Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 4/20 | 0.59 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.58 |
| ▸ | PSEN1 | P49768 | 6/20 | 0.47 |
| ▸ | PSEN2 | P49810 | 6/20 | 0.47 |
| ▸ | APH1B | Q8WW43 | 6/20 | 0.47 |
| ▸ | NCSTN | Q92542 | 6/20 | 0.47 |
| ▸ | APH1A | Q96BI3 | 6/20 | 0.47 |
| ▸ | PSENEN | Q9NZ42 | 6/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 5/20 | 0.46 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.45 |
| ▸ | UHRF1 | Q96T88 | 1/20 | 0.43 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.43 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | WNT3A | P56704 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17517227 | 0.90 | DYRK1A (0.49) | KIF11DYRK1APSEN1PSEN2APH1B | |
| SCHEMBL20053046 | 0.89 | DYRK1A (0.47) | KIF11DYRK1APSEN1PSEN2APH1B | |
| SCHEMBL18674430 | 0.85 | DYRK1A (0.49) | KIF11DYRK1APSEN1PSEN2APH1B | |
| SCHEMBL14258707 | 0.83 | PSEN1 (0.59) | KIF11DYRK1APSEN1PSEN2APH1B | |
| SCHEMBL30010944 | 0.83 | PSEN1 (0.59) | KIF11DYRK1APSEN1PSEN2APH1B | |
| SCHEMBL30011735 | 0.81 | KIF11 (0.66) | KIF11DYRK1APSEN1PSEN2APH1B | |
| SCHEMBL22426536 | 0.81 | KIF11 (0.66) | KIF11DYRK1APSEN1PSEN2APH1B | |
| SCHEMBL1896511 | 0.81 | DYRK1A (0.65) | DYRK1APSEN1PSEN2APH1BNCSTN | |
| SCHEMBL30308690 | 0.81 | DYRK1A (0.65) | DYRK1APSEN1PSEN2APH1BNCSTN | |
| SCHEMBL17517228 | 0.81 | DYRK1A (0.40) | KIF11DYRK1APSEN1PSEN2APH1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115362151-B | Arylpiperidines as monoacylglycerol lipase modulators | 詹森药业有限公司 | 2025-02-11 | — | — | CN | disclosed |
| US-20240092781-A1 | ARYL PIPERIDINES AS MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2024-03-21 | — | — | US | disclosed |
| US-11787798-B2 | Aryl piperidines as monoacylglycerol lipase modulators | JANSSEN PHARMACEUTICA NV (BE) | 2023-10-17 | — | — | US | disclosed |
| US-11787798-B2 | Aryl piperidines as monoacylglycerol lipase modulators | JANSSEN PHARMACEUTICA NV (BE) | 2023-10-17 | — | — | US | disclosed |
| US-11787798-B2 | Aryl piperidines as monoacylglycerol lipase modulators | JANSSEN PHARMACEUTICA NV (BE) | 2023-10-17 | — | — | US | disclosed |
| US-11701370-B2 | Phosphonium ion channel blockers and methods for use | Nocion Therapeutics, Inc. (US) | 2023-07-18 | — | — | US | disclosed |
| US-11701370-B2 | Phosphonium ion channel blockers and methods for use | Nocion Therapeutics, Inc. (US) | 2023-07-18 | — | — | US | disclosed |
| US-11643404-B2 | Ester substituted ion channel blockers and methods for use | Nocion Therapeutics, Inc. (US) | 2023-05-09 | — | — | US | disclosed |
| US-11643404-B2 | Ester substituted ion channel blockers and methods for use | Nocion Therapeutics, Inc. (US) | 2023-05-09 | — | — | US | disclosed |
| CN-115362151-A | Aryl piperidines as monoacylglycerol lipase modulators | 詹森药业有限公司 | 2022-11-18 | — | — | CN | disclosed |
| US-20200290965-A1 | CHARGED ION CHANNEL BLOCKERS AND METHODS FOR USE | Nocion Therapeutics, Inc. | 2020-09-17 | — | — | US | disclosed |
| US-20200290953-A1 | Charged Ion Channel Blockers and Methods for Use | Nocion Therapeutics, Inc. | 2020-09-17 | — | — | US | disclosed |
| US-20200290991-A1 | ESTER SUBSTITUTED ION CHANNEL BLOCKERS AND METHODS FOR USE | Nocion Therapeutics, Inc. | 2020-09-17 | — | — | US | disclosed |
| US-9073892-B2 | Indazolyl triazol derivatives | MERCK SERONO S.A. (CH) | 2015-07-07 | — | — | US | disclosed |
| US-9073892-B2 | Indazolyl triazol derivatives | MERCK SERONO S.A. (CH) | 2015-07-07 | — | — | US | disclosed |
| US-8791104-B2 | 1,4-benzodiazepine-2,5-diones with therapeutic properties | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2014-07-29 | — | — | US | disclosed |
| US-20130274241-A1 | INDAZOLYL TRIAZOL DERIVATIVES | MERCK SERONO S.A. - INTELLECTUAL PROPERTY (CH) | 2013-10-17 | — | — | US | disclosed |
| US-20130274241-A1 | INDAZOLYL TRIAZOL DERIVATIVES | MERCK SERONO S.A. - INTELLECTUAL PROPERTY (CH) | 2013-10-17 | — | — | US | disclosed |
| US-20130261110-A1 | NOVEL 1,4-BENZODIAZEPINE-2,5-DIONES WITH THERAPEUTIC PROPERTIES | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2013-10-03 | — | — | US | disclosed |
| US-20120088757-A1 | NOVEL 1,4-BENZODIAZEPINE-2,5-DIONES WITH THERAPEUTIC PROPERTIES | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2012-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200290953-A1 | Charged Ion Channel Blockers and Methods for Use | TRPV1, TRPV2, TRPV5 | KIF11 2954/4885DYRK1A 4362/4885PSEN1 1081/4885 |
| US-20240092781-A1 | ARYL PIPERIDINES AS MONOACYLGLYCEROL LIPASE MODULATORS | MGLL, LPL, PNLIP | KIF11 4330/4885DYRK1A 3032/4885PSEN1 1158/4885 |
| US-20130261110-A1 | NOVEL 1,4-BENZODIAZEPINE-2,5-DIONES WITH THERAPEUTIC PROPERTIES | BAD, GABRA5, GABRB1 | KIF11 4574/4885DYRK1A 1178/4885PSEN1 446/4885 |
| US-11787798-B2 | Aryl piperidines as monoacylglycerol lipase modulators | MGLL, LPL, PNLIP | KIF11 4330/4885DYRK1A 3032/4885PSEN1 1158/4885 |
| US-20130274241-A1 | INDAZOLYL TRIAZOL DERIVATIVES | NFATC1, IL5, CD4 | KIF11 4231/4885DYRK1A 3535/4885PSEN1 3954/4885 |
| US-20200290991-A1 | ESTER SUBSTITUTED ION CHANNEL BLOCKERS AND METHODS FOR USE | TRPV1, TRPA1, TRPV2 | KIF11 3688/4885DYRK1A 4615/4885PSEN1 1134/4885 |
| US-20200290965-A1 | CHARGED ION CHANNEL BLOCKERS AND METHODS FOR USE | TRPV1, TRPV2, TRPV5 | KIF11 2954/4885DYRK1A 4362/4885PSEN1 1081/4885 |
| US-11701370-B2 | Phosphonium ion channel blockers and methods for use | TRPV1, TRPV5, TRPA1 | KIF11 3693/4885DYRK1A 3474/4885PSEN1 341/4885 |
| US-11643404-B2 | Ester substituted ion channel blockers and methods for use | TRPV1, TRPA1, TRPV2 | KIF11 3688/4885DYRK1A 4615/4885PSEN1 1134/4885 |
| US-20120088757-A1 | NOVEL 1,4-BENZODIAZEPINE-2,5-DIONES WITH THERAPEUTIC PROPERTIES | BAD, GABRA5, GABRB1 | KIF11 4574/4885DYRK1A 1178/4885PSEN1 446/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.